10:59 AM EDT, 04/07/2025 (MT Newswires) -- Tharimmune ( THAR ) reported Monday preclinical data from its expanded pipeline featuring dual-target biologics HS1940 and HS3215, which it says was "positive."

HS1940 is designed to bind to both programmed death-1, or PD-1, and vascular endothelial growth factor, or VEGF, potentially improving treatment outcomes for various cancers. HS3215 targets human epidermal growth factor receptors 2 and 3, or HER2 and HER3, key proteins involved in cancer growth. HS1940 and HS3215 were developed using Tharimmune's ( THAR ) antibody engineering platform, EpiClick Technology, the company said.

The company also said it aims to further improve the binding characteristics of HS1940 and present more data at future conferences, with plans to begin investigational new drug, or IND-enabling studies in 2025. Tharimmune ( THAR ) also said it is conducting preclinical studies on HS3215 and plans to advance it into clinical trials after IND-enabling studies.

Shares of Tharimmune ( THAR ) were down nearly 7% in recent trading.

Price: 1.10, Change: -0.08, Percent Change: -6.86